Kevin J Scanlon

Title: Kevin J. Scanlon: Innovator in Genetic Therapeutics

Introduction

Kevin J. Scanlon is a prominent inventor based in Pasadena, CA, known for his significant contributions to the field of genetic therapeutics. With a total of 8 patents to his name, Scanlon has focused on innovative solutions that address critical health issues related to drug and radiation resistance.

Latest Patents

Among his latest patents is the groundbreaking work on the modulation of drug and radiation resistant genes. One notable patent involves the ribozyme cleavage of 5.alpha.-reductase mRNA. The steroid enzyme 5.alpha.-reductase plays a crucial role in converting testosterone into the more potent androgen dihydrotestosterone (DHT). Scanlon's research demonstrates that the catalytic cleavage of nucleic acid encoding 5.alpha.-reductase by a ribozyme selectively reduces the expression levels of this enzyme in mammalian cells, including human cells. This reduction leads to a corresponding decrease in DHT levels in surrounding tissues, providing a potential therapeutic effect. His work also includes pharmaceutical compositions and methods for topically administering effective amounts of such ribozymes to hair follicle cells.

Career Highlights

Throughout his career, Scanlon has worked with esteemed institutions such as City of Hope and the University of California. His innovative research has paved the way for advancements in genetic therapies, particularly in the treatment of conditions related to hormone regulation.

Collaborations

Kevin J. Scanlon has collaborated with notable colleagues, including Lawrence C. Sowers and Mohammed Kashani-Sabet, further enhancing the impact of his research through shared expertise and knowledge.

Conclusion

Kevin J. Scanlon's contributions to the field of genetic therapeutics exemplify the power of innovation in addressing complex health challenges. His work continues to inspire advancements in medical science and therapeutic applications.